Clinical trial
A Phase I Multiple Oral, Rising-Dose, Tolerance and Pharmacokinetic Trial of CI-1012 in HIV-1-Infected Volunteers.
NCT00002196 is registered in ClinicalTrials.gov with Parke-Davis as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Multiple Oral, Rising-Dose, Tolerance and Pharmacokinetic Trial of CI-1012 in HIV-1-Infected Volunteers.
- Lead sponsor
- Parke-Davis
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- Not reported
- Completion date
- Not reported
- Enrollment
- 32
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.